The US FDA has granted breakthrough device designation to the company’s Acolyte Image Guided Crossing and Re-Entry Catheter System for treating coronary chronic total occlusions (CTOs)
The Acolyte system positions guidewires and catheters properly into the coronary vasculature to treat coronary CTOs patients whose symptoms persist post-medical therapy
The device further offers real-time optical coherence tomography (OCT) visualization & navigation capabilities for placing guidewires and catheters into the target vessel’s true lumen enabling CTO crossing to improve surgeries
Ref: Simpson | Image: Simpson
Related Newswire:- Vicore’s Almee Receives the US FDA’s Breakthrough Device Designation for Pulmonary Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
